TGTX
TG Therapeutics Hits Stride as Q2 2026 Results Show Strong Execution and Future Potential
TG Therapeutics, a biopharmaceutical company focused on developing treatments for various diseases, has announced its strong execution in the second quarter of 2026. According to the company's recent conference call transcript, the quarter marked an important evolution for TG Therapeutics, as it continues to establish BRIUMVI as a